58749-47-6

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Hydroxy-4-methoxy-2-nitro-benzaldehyde is used as an intermediate in the synthesis of pharmaceuticals for its versatile chemical properties and reactivity, contributing to the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Production:
In the agrochemical industry, 5-hydroxy-4-methoxy-2-nitro-benzaldehyde is used as a key component in the production of various agrochemicals, such as pesticides and herbicides, due to its ability to form stable and effective compounds.
Used in Dye Manufacturing:
5-Hydroxy-4-methoxy-2-nitro-benzaldehyde is utilized as a starting material in the manufacturing of dyes, taking advantage of its chemical structure to produce a range of colors for various applications, including textiles and printing inks.
Used in Organic Synthesis:
As a building block in organic synthesis, 5-hydroxy-4-methoxy-2-nitro-benzaldehyde is employed for the creation of various functional materials and compounds, showcasing its versatility and importance in the field of organic chemistry.
Used in Research and Development:
5-Hydroxy-4-methoxy-2-nitro-benzaldehyde is used in research and development for its potential antimicrobial and antioxidant properties, as well as its applications in the synthesis of new materials and compounds, driving innovation and advancements in various scientific fields.

InChI:InChI=1/C8H7NO5/c1-14-8-3-6(9(12)13)5(4-10)2-7(8)11/h2-4,11H,1H3

Upstream product

• 621-59-0 isovanillin 
• 77-78-1 dimethyl sulfate 
• 67-56-1 methanol 
• 712-97-0 6-nitro-1,3-benzodioxole-5-carbaldehyde 
• 58662-50-3 2-aldehyde-4-benzyloxy-5-methoxy nitrobenzene 

Downstream Products

• 15937-14-1 5-ethoxy-4-methoxy-2-nitro-benzaldehyde 
• 637347-73-0 5-(tert-butyldimethylsilyloxy)-4-methoxy-2-nitrobenzaldehyde 
• 112919-68-3 5-acetoxy-4-methoxy-2,β-dinitrostyrene 
• 1387641-54-4 7-methoxy-6-[2-(2-methoxy-ethoxy)-ethoxy]-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid [5-(3-chloro-benzylcarbamoyl)-2-methyl-phenyl]amide 
• 1387641-86-2 2-amino-4-methoxy-5-[2-(2-methoxy-ethoxy)-ethoxy]-benzaldehyde 
• 1387641-85-1 4-methoxy-5-[2-(2-methoxy-ethoxy)-ethoxy]-2-nitro-benzaldehyde 
• 194360-76-4 4-methoxy-2-nitro-3-pentyloxybenzaldehyde 
• 61948-83-2 5-ethoxy-4-methoxy-2-nitro-benzoic acid 
• 98258-77-6 (E)-5-hydroxy-4-methoxy-2,β-dinitrostyrene 

Relevant academic research and scientific papers

Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations

Targeted concurrent inhibition of intestinal drug efflux transporter P-glycoprotein (P-gp) and drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is a promising approach to improve oral bioavailability of their common substrates such as docetaxel, while avoiding side effects arising from their pan inhibitions. Herein, we report the discovery and characterization of potent small molecule inhibitors of P-gp and CYP3A4 with encequidar (minimally absorbed P-gp inhibitor) as a starting point for optimization. To aid in the design of these dual inhibitors, we solved the high-resolution cryo-EM structure of encequidar bound to human P-gp. The structure guided us to prudently decorate the encequidar scaffold with CYP3A4 pharmacophores, leading to the identification of several analogues with dual potency against P-gp and CYP3A4. In vivo, dual P-gp and CYP3A4 inhibitor 3a improved the oral absorption of docetaxel by 3-fold as compared to vehicle, while 3a itself remained poorly absorbed.

Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents

Structure-activity relationships for a series of 3-phenoxy-1,4-diarylazetidin-2-ones were investigated, leading to the discovery of a number of potent antiproliferative compounds, including trans-4-(3-hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (78b) and trans-4-(3-amino-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (90b). X-ray crystallography studies indicate the potential importance of the torsional angle between the 1-phenyl A ring and 4-phenyl B ring for potent antiproliferative activity and that a trans configuration between the 3-phenoxy and 4-phenyl rings is generally optimal. These compounds displayed IC50 values of 38 and 19 nM, respectively, in MCF-7 breast cancer cells, inhibited the polymerization of isolated tubulin in vitro, disrupted the microtubular structure in MCF-7 cells as visualized by confocal microscopy, and caused G2/M arrest and apoptosis. Compound 90b possessed a mean GI50 value of 22 nM in the NCI60 cell line screen, displayed minimal cytotoxicity, and was shown to interact at the colchicine-binding site on β-tubulin. Phosphate and amino acid prodrugs of both 78b and 90b were synthesized, of which the alanine amide 102b retained potency and is a promising candidate for further clinical development.

CARBOXYLIC ACID ARYL AMIDES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer.

PROCESS FOR THE PREPARATION OF GEFITINIB

There is provided a compound of formula (III), and a process for preparing a compound of formula (V) comprising converting a compound of formula (III) to the compound (V), wherein (X) is fluoro, chloro, bromo or iodo. There is also provided a process for preparing a compound of formula (Xl) comprising converting a compound of formula (X) to the compound (Xl). The compounds (V) and (Xl) so prepared may be used in a process for preparing gefitinib.

Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3′,4′,5′-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents

6-Methoxy-3-(3′,4′,5′-trimethoxybenzoyl)-1H-indole (BPR0L075) (1) is a potent inhibitor of tubulin polymerization which exhibits both in vitro and in vivo activities against a broad spectrum of solid tumors. This compound was designed as a heterocyclic an

2-oxoquinoline compounds and medicinal uses thereof

A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]: ? (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its pharmaceutically acceptable salts selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or antiallergic action. Therefore, these compounds are useful as cannabinoid receptors (particularly peripheral type cannabinoid receptors) modulator, immunosuppressants, anti-inflammatory agents, and antiallergic agents.

FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF

AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.

Compounds and pharmaceutical use thereof

PCT No. PCT/JP97/00291 Sec. 371 Date Aug. 6, 1998 Sec. 102(e) Date Aug. 6, 1998 PCT Filed Feb. 6, 1997 PCT Pub. No. WO97/29079 PCT Pub. Date Aug. 14, 1997The compounds of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The Compound (I) and pharmaceutically acceptable salts thereof of the present invention selectively act on cannabinoid receptors, particularly peripheral receptors, cause less side effects on the central system, and have superior immunoregulating action, antiinflammatory action, antiallergic action and therapeutic effect on nephritis. Therefore, they are useful as cannabinoid receptor, particularly peripheral cannabinoid receptor activators and antagonists, immunoregulators, therapeutic agents for autoimmune diseases, antiinflammatory agents, antiallergic agents and therapeutic agents for nephritis.

Antimicrobial indolequinones from the mid-intestinal gland of the muricid gastropod Drupella fragum

Three new indolequinones, 6-methoxyindole-4,7-quinone (1), 5- methoxyindole-4,7-quinone (2) and 5-methylindole-4,7-quinone (3) were isolated from the mid-intestinal gland of the muricid gastropod Drupella fragum. The structures of 1 and 2 were established

Facile synthesis of a o-nitrobenzyl photolabile linker for combinatorial chemistry

Two facile syntheses are described of the o-nitrobenzyl alcohol photolabile linker (5). This compound is a valuable intermediate in the preparation of combinatorial libraries, where it allows release from the solid support to give libraries of acids.